Halozyme Therapeutics, Inc. Revenue 2009–2025
Halozyme Therapeutics, Inc. reported $1.40B of revenue for fiscal 2025. That was 37.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +421.9%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $1.40B | +37.6% |
| FY 2024 | $1.02B | +22.4% |
| FY 2023 | $829.25M | +25.6% |
| FY 2022 | $660.12M | +48.9% |
| FY 2021 | $443.31M | +65.7% |
| FY 2020 | $267.59M | +36.5% |
| FY 2019 | $195.99M | +29.1% |
| FY 2018 | $151.86M | -52.0% |
| FY 2017 | $316.61M | +115.8% |
| FY 2016 | $146.69M | +8.6% |
| FY 2015 | $135.06M | +79.3% |
| FY 2014 | $75.33M | +37.5% |
| FY 2013 | $54.80M | +29.5% |
| FY 2012 | $42.33M | -24.5% |
| FY 2011 | $56.09M | +311.7% |
| FY 2010 | $13.62M | -0.3% |
| FY 2009 | $13.67M | — |
Source: Halozyme Therapeutics, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HALO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Halozyme Therapeutics, Inc. reported $1.40B of revenue for fiscal 2025. That was 37.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +421.9%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Halozyme Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHalozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s revenue?
Halozyme Therapeutics, Inc. (HALO) reported revenue of $1.40B for fiscal year 2025, per its SEC filings.
How has Halozyme Therapeutics, Inc.'s revenue changed over time?
Between fiscal 2009 and 2025, HALO's revenue grew at roughly 33.5% per year (compound annual rate), from $13.67M to $1.40B.
Where does this data come from?
Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.